Physician and Payer Attitudes and the Impact of the Aging Population
Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating diseases related to aging. In China, the prevalence of AD is estimated to be 4 million in 2015. The sheer number of prevalent cases, on top of the difficulty of diagnosis and the hefty cost associated with caring for AD patients, could pose significant demands on the healthcare and long-term care infrastructures in China. There is currently no cure for AD, and standard pharmacological interventions such as acetylcholinesterase inhibitors (AChEIs, e.g., donepezil and huperzine A) and memantine (Lundbeck’s Ebixa) merely slow patients’ cognitive and functional deterioration without impeding the neurodegenerative processes. As a result, there is still a huge market demand for novel disease-modifying agents for AD and the emergence of novel disease-modifying agents that can delay disease progression may help to alleviate this healthcare burden in China.
Questions Answered in This Report:
- Current therapies for AD in China: What are the current prescribing patterns for AChEIs and memantine? How do physicians expect these patterns to evolve over the next few years? What factors are driving/constraining physician prescribing of AD drugs? How commonly are physicians prescribing AChEIs and memantine combination therapies?
- Market access opportunities and challenges of AD drugs in China: What is the reimbursement landscape for AChEIs and memantine? What reimbursement restrictions apply to AChEIs and memantine? How do reimbursement restrictions affect the prescribing of current therapies in different provinces/municipalities? What are payers’ views on the pricing and reimbursement landscape for emerging anti-dementia drugs?
- Emerging therapies for AD in China: How do physicians and payers perceive new anti-dementia drugs under Phase III clinical development in China? What therapies do payers expect to be included in the new versions of the National Reimbursement Drug List (NRDL) and/or Provincial Reimbursement Drug Lists (PRDLs)?
Markets covered: China.
- 50 neurologists/psychiatrists/geriatricians complete an online quantitative survey designed by therapeutic and country experts.
- Three interviews with payers/payer-advising thought leaders who have influence on patient access to AD drugs at a regional or national level.
Epidemiology: Total and diagnosed prevalent cases of AD.
Emerging therapies: Phase III: three drugs.
Qi Li, M.B., Ph.D.